A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00087724 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

510

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: FK962

Sponsor

Astellas Pharma Inc

Collaborators

[object Object]